Is PMVP or PRME more undervalued in 2026?

CirclFi compares PMV Pharmaceuticals, Inc. (PMVP) and Prime Medicine, Inc. (PRME) using 13 institutional-grade valuation models. PMVP has a Quality of Company score of 4.5/10 while PRME scores 5.1/10.

Which is a better buy — PMVP or PRME?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do PMVP and PRME valuations compare?

PMVP at $1.19 and PRME at $3.40 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

PMVP vs PRME Valuation Comparison 2026 — Intrinsic Value Analysis

PMVP

Biotechnology

PMV Pharmaceuticals, Inc.

Quality

4.5

out of 10

Value Trap

SAFE

Price

$1.19

Last close

Models

9/13

Active

PRME

Biotechnology

Prime Medicine, Inc.

Quality

5.1

out of 10

Value Trap

LOW

Price

$3.40

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	PMVP Fair Value	PMVP Upside	PRME Fair Value	PRME Upside
Bayesian DCF	Intrinsic	$0.52	-56.2%	$0.85	-75.0%
Earnings Power Value	Intrinsic	$0.94	-32.7%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.19	-86.6%	$0.82	-75.9%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for PMVP vs PRME — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PMVP vs PRME — Which Stock Is More Undervalued?

PRME scores higher with a 5.1/10 quality rating vs PMVP's 4.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing PMV Pharmaceuticals, Inc. (PMVP) and Prime Medicine, Inc. (PRME) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PMVP currently trades at $1.19 with a QOC of 4.5/10, while PRME trades at $3.40 with a QOC of 5.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).